Table 2 Incidence rates and hazard ratios of vancomycin compared to all comparators and vancomycin compared to singular comparator.

From: The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics

 

N

Cases

Person timeb

Incidence rateb

95% CI

Crude HR

95% CI

Adjusted HRc

95% CI

Vancomycina

5449

22

22.35

0.93

0.94–1.92

    

Comparators

27,548

107

113.93

0.96

0.77–1.12

1.04

0.85–1.90

0.74

0.45–1.21

Cefazolin

20,124

58

83.31

0.69

0.53–0.89

1.40

0.86–2.29

1.01

0.55–1.83

Linezolid

251

6

1.03

5.76

2.59–12.83

0.17

0.07–0.42

0.17

0.01–0.46

Piperacillin

3885

25

16.00

1.54

1.04–2.28

0.63

0.35–1.11

0.47

0.24–0.91

Cefepime

433

2

1.79

1.11

0.28–4.43

0.87

0.45–3.70

0.80

0.19–3.69

Meropenem

379

7

1.58

4.44

2.12–9.32

0.22

0.09–0.51

0.21

0.10–0.52

Ertapenem

2205

8

9.13

0.86

0.43–1.73

1.11

0.51–2.50

0.47

0.19–1.17

Daptomycin

271

1

1.12

0.88

0.12–6.25

1.09

0.15–8.11

0.99

0.12–8.19

  1. 95% CI 95% confidence interval, HR hazard ratio.
  2. aIndex group.
  3. bPer 10 person-years.
  4. cAdjusted for age, gender, medical history, co-medication, type of surgery, main diagnosis (not Included in model because of low cell count: vancomycin vs. piperacillin ,vancomycin vs. ertapenem, vancomycin vs. daptomycin, and vancomycin vs. cefepime).
Back to article page